Your browser does not support JavaScript!
:::
Examinee
:::
Ching-Ping Tseng

Ching-Ping Tseng

Highest Degree

Ph. D. in Human Cancer Biology University

 of Wisconsin-Madison

 

 

 


 

Areas of Specialty

Cancer Biology, Platelet Biology Molecular Diagnostics, Molecular and Cellular  Biology

Office Phone

5202

Lab phone

5216

Research website:

https://sites.google.com/site/ctsenglab/

E-mail

ctsengmail.cgu.edu.tw

Lab & Research Interest

Molecular analysis of the interplay between tumor microenvironment and cancer progression

Cancer is one of the major causes of death worldwide and has a significant impact on national health. During cancer progression, tumor cells are confronted with platelet and various plasma proteins in the bloodstream that has been defined as the third microenvironment in addition to the primary tumor site (the primary tumor microenvironment) and the distant metastatic organs (the second tumor microenvironment). Experimental and clinical data all indicate that tumor cell interacting with platelets and the clotting system are important elements of tumor progression and cancer cells metastasis leading to the development of advanced stage cancer. Abrogation of cancer cell-platelet interaction thereby provides an attractive target for development of innovative cancer therapeutic regimens. We aim to identify novel regulators that are crucial for cancer cell-platelet interactions using various molecular and cellular approaches. A number of in vivo and in vitro study models have been established that can be applied for target gene discovery and analysis. Several regulators that mediate cancer cell-platelet interactions are candidates for translating to clinical application and are under intensive investigation.

 

Molecular analysis of platelet function and platelet biogenesis

Platelet is important in various physiological and pathological conditions, including hemostasis, thrombosis, and cancer. Understanding the mechanistic insight of platelet biogenesis and signaling can contribute to the development of effective therapy for thrombosis, thrombocytopenia, and cancer. Although it has been known for years that each megakarycoyte produces about 5000 platelets through the formation of proplatelet with thin tread structure protruding from the megakaryocytes, the key regulators in the control of megakaryocytic differentiation and platelet biogenesis are not yet completely understood. At present, the murine embryonic stem cells-OP9 coculture system and the lineage-specific DAB2 knockout mice are used as the study model to elucidate the functional role of the adaptor protein Disabled-2 (DAB2) in the regulation of megakaryocytic differentiation, proplatelet formation and platelet function. We expect to gain new insight on the mechanisms underlying megakaryocytic maturation and platelet biogenesis that should provide information on how functional platelets are produced in physiological condition and how to obtain and maintain appropriate platelet count under pathological condition.

Publication

1.        Chong K-Y, Tseng C-P, and Tsai W-C. The susceptibility pattern of fifteen common clinical bacteria against different cephalosporins. J. Biomed. Lab. Sci. 2:12-23, 1989.

2.        Tseng C-P, Kim Y-J, Kumar R, and Verma AK. Involvement of protein kinase C in the transcriptional regulation of 12-O-tetradecanoylphorbol-13-acetate-inducible genes  modulated  by AP-1 or non-AP-1 transacting factors. Carcinogenesis 15:707-711, 1994. (SCI)

3.        Tseng C-P, and Verma AK. Lack of 12-O-tetradecanoylphorbol-13-acetate responsiveness of ornithine decarboxylase introns which have AP-1 consensus sequence. Mol. Cell. Biochem. 146:7-12, 1995. (SCI)

4.        Tseng C-P, and Verma AK. Functional expression and characterization of epitope-tag protein kinase C isoforms a, bI, bII, g, d, and e. Gene 169:287-288, 1996. (SCI)

5.        Tseng C-P, and Verma AK. Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced ornithine decarboxylase activity by genistein, a tyrosine kinase inhibitor. Mol. Pharmacology 50:249-257, 1996. (SCI)

6.        Tseng C-P, Ely BD, Li Y, Pong RC, and Hsieh JT. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 139:3542-3553, 1998. (SCI)

7.        Li Y, Pong RC, Hall MC, Tseng C-P, Wang Z, Sagalowsky AL, Bergelson JM, and Hsieh JT. Lack of adenoviral receptor expression in human bladder cancer cells – a potential impact on the efficacy of gene therapy. Cancer Research 59:325-330, 1999. (SCI)

8.        Tseng C-P, Ely BD, Pong RC, Li Y, Wang Z, Cobb MH, and Hsieh JT. The role of rat DOC-2 protein phosphorylation in the negative regulation of AP-1 activity – an underlying mechanism of its tumor suppressive function. J. Biol. Chem. 274:31981-31986, 1999. (SCI)

9.        Reddig PJ, Dreckschimdt NE, Ahrens H, Simsiman R, Tseng C-P, Zou J, Oberley T, and Verma AK.  Transgenic mice overexpressing protein kinase Cd in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA). Cancer Research 59:5710-5718, 1999. (SCI)

10.     Tseng C-C, and Tseng C-P.  Identification of a novel secretory leukocyte protease inhibitor-binding protein involved in membrane phospholipid movement. FEBS Lett. 475:232-236, 2000. (SCI)

11.     Tseng C-C, Tseng C-P, Levine MJ, and Bobek LA. Differential effect towards inhibition of papain and cathepsin C by recombinant human salivary cystatin SN and its variants produced by a baculovirus system.  Arch. Biochem. Biophys. 380:133-140, 2000. (SCI)

12.     Tseng C-H, Tai T-Y, Chong C-K, Tseng C-P, Lai M-S, Lin BJ, Chiou H-Y, Hsueh Y-M, Hsu K-H, and Chen C-J. Long-Term Arsenic Exposure and Incidence of Non-Insulin-Dependent Diabetes Mellitus: A Cohort Study in Arseniasis-Hyperendemic Villages in Taiwan.  Environ. Health. Perspect. 108:847-851, 2000. (SCI)

13.     Lin M-H, Chen T-C, Kuo T-T, Tseng C-C, and Tseng C-P (Corresponding author). Development of real-time quantitative polymerase chain reaction for the detection of Toxoplasma gondii. J. Clin. Microbiology 38:4121-4125, 2000. (SCI)

14.     Tseng C-H, Chong C-K, Heng L-T, Tseng C-P, and Tai TY. The incidence of type 2 diabetes mellitus in Taiwan.  Diabetes Res Clin Pract 50 Suppl 2:S61-4, 2000. (SCI)

15.     Shih L-Y, Lin T-L, Dunn P, Wu J-H, Tseng C-P, Lai C-L, Wang P-N, and Kuo M-C. Clonality analysis using X-chromosome inactivation patterns by HUMARA-PCR assay in female controls and patients with idiopathic thrombocytosis in Taiwan. Exp. Hematology 29:202-208, 2001. (SCI)

16.     Tseng C-P (Corresponding author), Huang C-H, Tseng C-C, Lin M-H, Hsieh JT, and Tseng C-H. Induction of Disabled-2 gene during megakaryocyte differentiation of K562 cells. Biochem. Biophys. Res. Commun. 285:129-135, 2001. (SCI)

17.     Lin M-H, Tseng C-H, Tseng C-C, Huang C-H, Chong C-K, and Tseng C-P (Corresponding author). Real-time PCR for rapid genotyping of angiotensin-converting enzyme insertion/deletion polymorphism. Clin. Biochem. 34:661-666, 2001. (SCI)

18.     Chu DC, Chuang CK, Fu JB, Huang H-S, Tseng C-P, and Sun CF. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J. Urology. 167:1854-1858, 2002. (IF = 4.053, Urology & Nephrology 8/55)

19.     Wang Z, Tseng C-P, Pong RC, Chen H, McConnell JD, Navone N, and Hsieh JT. The mechanism of growth inhibitory effect of DOC-2/DAB2 in prostate cancer: Characterization of a novel GTPase activating protein associated with N-terminal domain of DOC-2/DAB2. J. Biol. Chem. 277:12622-12631, 2002. (IF = 5.581, Biochemistry and Molecular Biology 40/263)

20.     Tseng C-H, Tseng C-P, Chiou HY, Hsueh YM, Chong CK, and Chen CJ. Epidemiologic evidence of diabetogenic effect of arsenic. Toxicol. Lett. 133:69-76, 2002. (IF = 2.826, Toxicology 17/73)

21.     Tseng C-P (Corresponding author), Cheng AJ, Chang JTC, Tseng CH, Wang HM, Liao CTL, Chen IH, and Tseng CC.  Development of real-time RT-PCR for quantitative analysis of multidrug resistant mdr1 gene expression in oral cancer. Japanese J. Cancer Res. 93:1230-1236, 2002. (IF = 3.165, Oncology 53/132)

22.     Tseng CH, and Tseng C-P. Lack of association between angiotensin-converting enzyme gene polymorphism and peripheral vascular disease in type 2 diabetic patients in Taiwan. Circ. J. 66:1014-1018, 2002. (IF = 2.373, Cardiac & Cardiovascular Systems 25/74)

23.     Tseng CH, Tseng C-P, and Chong CK. Aging and current perception threshold measured by neurometer in normal Taiwanese adults. J. Amer. Geriatr. Soc. 50:2094-2095, 2002. (IF = 3.539, Geriatrics & Gerontology 7/31)

24.     Chen DP, Tsao KC, Wang PN, Tseng C-P, and Sun CF. Quantitative analysis of chimerism after allogeneic peripheral blood stem cell transplantation. Chang Gung Med. J. 25:734-742, 2002.

25.     Tseng CH, Chong CK, Tseng C-P, Hsueh YM, Chiou HY, Tseng CC, and Chen CJ.  Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol. Lett. 137:15-21, 2003. (IF = 2.826, Toxicology 17/73)

26.     Tseng C-P, Cheng JC, Tseng CC, Wang C, Chen YL, Chiu DTY, Liao HC, and Chang SS. Broad-range ribosomal RNA real-time PCR after removal of DNA from reagents: melting profiles for clinically important bacteria. Clin. Chem. 49:306-309, 2003. (IF = 4.803, Medical Laboratory Technology 2/26)

27.     Tseng C-P (corresponding author), Huang CL, Huang CH, Stern A, Cheng JC, Tseng CH, and Chiu DTY. Disabled-2 small interfering RNA modulates cellular adhesive function and MAPK activity during megakaryocytic differentiation of K562 cells. FEBS Letters 541:21-27, 2003. (IF = 3.263, Biochemistry and Molecular Biology 98/263)

28.     Chan YL*, Tseng C-P*, Tsay PK, Chang SS*, Chiu TF, and Chen JC. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Critical Care 8:R12-R20, 2004. (IF = 3.834, Critical Care Medicine 4/19) (*Equal contribution)

29.     Chen DP, Tseng C-P, Tsao KC, Wang WT, Peng CT, and Sun CF. Identification of a novel O allele in the Taiwanese population. Ann. Clin. Lab. Sci. 34:63-66, 2004 (IF = 1.065, Medical Laboratory Technology 18/26)

30.     Chang SS, Chan YL, Wu ML, Deng JF, Chiu TF, Chen JC, Wang FL, and Tseng C-P. Acute Cycas Seed Poisoning in Taiwan. Journal of Toxicology – Clinical Toxicology 42:49-54, 2004. (SCI)

31.     Chen DP, Tseng C-P, Yu LC, Wang WT, Peng CT, Lin KT, Wang YC, and Sun CF. Two h alleles are prevalent in para-Bombay haplotypes among 250,000 Taiwanese. Ann. Clin. Lab. Sci. 34:314-318, 2004. (IF = 1.065, Medical Laboratory Technology 18/26)

32.     Huang CL, Cheng JC, Liao CH, Stern A, Hsieh JT, Wang CH, Hsu HL, and Tseng C-P (Corresponding author). Disabled-2 is a negative regulator of integrin aIIbb3-mediated fibrinogen adhesion and cell signaling.  J. Biol. Chem. 279:42279-42289, 2004. (IF = 5.581, Biochemistry and Molecular Biology 40/263)

33.     Chen DP, Tseng C-P, Wang WT, Wang MC, Tsao KC, Wu TL, and Sun CF. A novel cis-AB allele derived from the A transferase gene by nucleotide substitution C796A. Ann. Clin. Lab. Sci. 34:437-442, 2004. (IF = 1.065, Medical Laboratory Technology 18/26)

34.     Chen DP, Tseng C-P, Wang WT, and Sun CF. Identification of a novel A2 allele derived from the A transferase gene through a nucleotide substitution G539C. Vox Sanguinis 88:196-199, 2005. (IF = 2.588, Hematology 28/63)

35.     Tseng CH, Chong CK, Sheu JJ, Wu TH, Tseng C-P. Prevalence and risk factors for stroke in Type 2 diabetic patients in Taiwan: a cross-sectional survey of a national sample by telephone interview. Diabet Med. 22:477-482, 2005. (IF = 2.970, Endocrinology & Metabolism 38/92)

36.     Chen DP, Tseng C-P, Lin HT, Sun CF. Application of real-time PCR and melting curve analysis in rapid detection of Ael and Bel blood types. Ann Clin Lab Sci. 35:25-30, 2005. (IF = 1.065, Medical Laboratory Technology 18/26)

37.     Zhou J, Hernandez G, Tu SW, Scholes J, Chen H, Tseng C-P, Hsieh JT. Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.  Cancer Res. 65:6089-6096, 2005. (IF = 7.672, Oncology 8/132)

38.     Tseng CH, Tseng C-P, Tai TY, Chong CK. Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in Taiwanese elderly patients with type 2 diabetes mellitus. Circ J. 69:965-970, 2005. (IF = 2.373, Cardiac & Cardiovascular Systems 25/74)

39.     Tseng C-P (Corresponding author), Chang P, Huang CL, Cheng JC, and Chang SS. Autocrine signaling of platelet-derived growth factor regulates Disabled-2 expression during megakaryocytic differentiation of K562 cells.  FEBS Letters, 579:4395-4401, 2005. (IF = 3.263, Biochemistry and Molecular Biology 98/263)

40.     Tseng C-P, Huang CL, Chong KY, Hung IJ, and Chiu DTY. Rapid detection of glucose-6-phosphate dehydrogenase gene mutations by denaturing high-performance liquid chromatography. Clin. Biochem. 38:973-980, 2005. (IF = 2.072, Medical Laboratory Technology, 9/26)

41.     Zhou J, Hernandez G, Tu SW, Huang CL, Tseng C-P, and Hsieh JT. The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res. 65:9906-9913, 2005. (IF = 7.672, Oncology 8/132)

42.     Tseng CH, Tseng C-P, Chong CK, Cheng JC, Tai TY. Independent association between triglycerides and coronary artery disease in Taiwanese type 2 diabetic patients. Int. J. Cardiol. 111:80-85, 2006. (IF = 2.878, Cardiac & Cardiovascular Systems 22/74)

43.     Chen JC, Lee WH, Chen PC, Tseng C-P, Huang EY. Rat NPFF(1) receptor-mediated signaling function comparison of neuropeptide FF (NPFF), FMRFamide and PFR(Tic)amide. Peptides 27:1005-1014, 2006. (IF = 2.368, Pharmacology & Pharmacy 84/205)

44.     Chang JT, Lu YC, Chen YJ, Tseng C-P, Chen YL, Fang CW, Cheng AJ. hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head and neck cancer cells. Br. J. Cancer 94:870-878, 2006. (IF = 4.635, Oncology 27/132)

45.     Sun CF, Chen DP, Tseng C-P, Wang WT, Liu JP. Identification of a novel A1v-O1v hybrid allele with G829A mutation in a chimeric individual of AelBel phenotype. Transfusion 46:780-789, 2006.  (IF = 3.374, Hematology 19/63)

46.     Tseng CH, Tseng C-P, Chong CK, Huang TP, Song YM, Chou CW, Lai SM, Tai TY, Cheng JC. Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort. Diabetologia. 49:1755-1760, 2006. (IF = 5.822, Endocrinology & Metabolism 10/92)

47.     Wu JY, Chang SS, Tseng C-P, Deng JF, Lee CC. Parenteral glyphosate-surfactant herbicide intoxication. Am J Emerg Med. 24:504-506, 2006. (IF = 1.164, Emergency Medicine 6/12)

48.     Huang CL, Cheng JC, Stern A, Hsieh JT, Liao CH, Tseng C-P (Corresponding author). Disabled-2 is a novel integrin aIIb-binding protein that negatively regulates platelet-fibrinogen interactions and platelet aggregation. J. Cell Sci. 119:4420-4430, 2006. (IF = 6.383, Cell Biology 28/156)

49.     Cheng JC, Huang CL, Lin CC, Chen CC, Chang YC, Chang SS, Tseng C-P (Corresponding author). Rapid detection and identification of clinically important bacteria by high-resolution melting analysis after broad-range ribosomal RNA real-time PCR. Clin. Chem. 52:1997-2004, 2006.  (IF = 4.803, Medical Laboratory Technology 2/26)

50.     Huang CH, Cheng JC, Chen JC, Tseng C-P (Corresponding author). Evaluation of the role of Disabled-2 in nerve growth factor-mediated neurite outgrowth and cellular signaling. Cell. Signal., 19:1339-1347, 2007. (IF = 4.147, Cell Biology 49/156)

51.     Tseng CH, Chong CK, Tseng C-P, Centeno JA. Blackfoot disease in Taiwan: its link with inorganic arsenic exposure from drinking water. Ambio 36:82-84, 2007. (IF = 1.487, Engineering, Environmental 11/37)

52.     Tseng CH, Tseng C-P, Chong CK, Sheu JJ, Cheng JC. Angiotensin-converting enzyme gene polymorphism and stroke in type 2 diabetic patients in Taiwan. Eur. J. Clin. Invest. 37:483-491, 2007.  (IF = 2.701, Medicine, General & Internal 22/100)

53.     Chen DP, Tsai SH, Tseng C-P, Wu TL, Chang PY, Sun CF. Bone marrow transplant relapse with loss of an allele. Clin Chim Acta. 387:161-164, 2008. (IF = 2.601, Medical Laboratory Technology 4/26)

54.     Huang YJ, Chen IS, Tseng C-P, Day YJ, Lin YC, Liao CH. (2R,3R)-2-(3',4'-dihydroxybenzyl)-3-(3'',4''-dimethoxybenzyl)butyrolactone suppresses fMLP-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. Biochem Pharmacol. 75:688-697, 2008. (IF = 4.006, Pharmacology & Pharmacy 32/205)

55.     Tseng CH, Chong CK, Tseng C-P, Tai TY. The association between urinary albumin excretion and ankle-brachial index in elderly Taiwanese patients with type 2 diabetes mellitus. Age Ageing. 37:77-82, 2008. (IF = 1.910, Geriatrics & Gerontology 18/31)

56.     Lin JH*, Tseng C-P*, Chen YJ, Lin CY, Chang SS, Wu HS, Cheng JC. Rapid differentiation of influenza A virus subtypes and genetic screening for virus variants by high-resolution melting analysis. J Clin Microbiol. 46:1090-1097, 2008 (IF = 3.708, Microbiology 20/94) (*Co-first author)

57.     Tseng CH, Chong CK, Tseng C-P, Cheng JC, Wong MK, Tai TY. Mortality, causes of death and associated risk factors in a cohort of diabetic patients after lower-extremity amputation: A 6.5-year follow-up study in Taiwan. Atherosclerosis 197:111-117, 2008. (IF = 4.287, Peripheral Vascular Disease 10/54)

58.     Wu YH, Tseng C-P, Cheng ML, Ho HY, Shih SR, Chiu DT. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. J Infect Dis. 197:812-816, 2008. (IF = 6.035, Infectious Disease 3/50)

59.     Wu CY, Hsieh HL, Sun CC, Tseng C-P, Yang CM. IL-1 beta induces proMMP-9 expression via c-Src-dependent PDGFR/PI3K/Akt/p300 cascade in rat brain astrocytes. J Neurochem. 105:1499-1512, 2008. (IF = 4.451, Neuroscience 37/211)

60.     Weng LP, Wu CC, Hsu BL, Chi LM, Liang Y, Tseng C-P, Hsieh LL, Yu JS. Secretome-based identification of Mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. Journal of Proteome Research 7:3765-3775, 2008 (IF = 5.151, In Press).

61.     Chen DP, Tseng C-P, Tsai SH, Wu TL, Chang PY, Sun CF. Systematic analysis of stutters to enhance the accuracy of chimerism testing. Ann Clin Lab Sci. 38:264-272, 2008.

62.     Tseng CH, Chong CK, Tseng C-P, Shau WY, Tai TY. Hypertension is the most important component of metabolic syndrome in the association with ischemic heart disease in Taiwanese type 2 diabetic patients. Circ J. 72:1419-1424, 2008.

63.     Liao CH, Lin SZ, Tseng C-P, Day YJ, Chang CS, Chang YH, Kuo SC. A benzodiazepines derived compound, 4-(3-chlorophenyl)-1,3-dihydronaphtho [2,3-b][1,4]diazepin-2-one (ND700C), inhibits fMLP-induced superoxide anion release by activating protein phosphatase 2A in human neutrophils. Biochem Pharmacol. 76:1728-1739, 2008.

64.     Tseng CH, Chong CK, Tseng C-P, Chan TT. Age-related risk of mortality from bladder cancer in diabetic patients: A 12-year follow-up of a national cohort in Taiwan. Ann Med. 41(5):371-9, 2009.

65.     Wang SY*, Tseng C-P*, Tsai KC, Lin CF, Wen CY, Tsay HS, Sakamoto N, Tseng CH, Cheng JC. Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq. Biochem Biophys Res Commun. 385:230-235, 2009. (Co-first authors)

66.     Yang CJ, Liu YK, Liu CL, Shen CN, Kuo ML, Su CC, Tseng C-P, Yen TC, Shen CR. Inhibition of acidic mammalian chitinase by RNA interference suppresses OVA-sensitized allergic asthma. Hum Gene Ther. 20:1597-1606, 2009.

67.     Chen DP*, Tseng C-P*, Tsai SH, Wang MC, Lu SC, Wu TL, Chang PY, Sun CF. Use of X-linked short tandem repeats loci to confirm mutations in parentage caseworks. Clin Chim Acta. 408:29-33, 2009. (*Co-first authors)

68.     Yang CM, Hsieh HL, Yao CC, Hsiao LD, Tseng C-P, Wu CB. Protein Kinase C-d transactivates platelet-derived growth factor receptor-a in mechanical strain-induced collagenase 3 (matrix metalloproteinase-13) expression by osteoblast-like cells. J Biol Chem. 284:26040-26050, 2009

69.     Tseng WL, Huang CL, Cheng JC, Liao CH, Stern A, Tseng C-P (Corresponding author). Reelin is a platelet protein and functions as a positive regulator of platelet spreading on fibrinogen. Cell. Mol. Life Sci. 67:641-653, 2010.

70.     Tseng CH, Tseng C-P, Chong CK. Joint effects of hypertension, smoking, dyslipidemia and obesity and angiotensin-converting enzyme DD genotype on albuminuria in Taiwanese patients with type 2 diabetes mellitus. Clin. Biochem. 43:629-34, 2010.

71.     Huang CL, Cheng JC, Kitajima K, Nakano T, Chong KY, Tseng C-P (Corresponding author). Disabled-2 is required for mesoderm differentiation of murine embryonic stem cells. J. Cell. Physiol. 225(1):92-105, 2010. (SCI; IF = 4.586, Physiology; Rank 7 of 75)

72.     Liao CH, Chen JJ, Lin JE, Liu CH, Tseng C-P, Day YJ. 5-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,7-dimethoxy-4H-chromen-4-one (MSF-2) suppresses fMLP-mediated respiratory burst in human neutrophils by inhibiting phosphatidylinositol 3-kinase activity. J. Cell. Physiol. 226:1519-1530, 2011. (SCI; IF = 4.586, Physiology; Rank 7 of 75)

73.     Lin HJ, Tseng C-P, Lin CF, Liao MH, Chen CM, Kao ST, Cheng JC. A Chinese herbal decoction, modified Yi Guan Jian, induces apoptosis in hepatic stellate cells through an ROS-mediated mitochondrial/caspase Pathway. Evid. Based Complement. Alternat. Med. 2011:459531, 2011. (SCI; IF = 2.064, Integrative and Complementary Medicine; Rank 3 of 17)

74.     Chen DP, Tseng C-P (Co-first author), Wang WT, Wang MC, Tsai SH, Sun CF. Real-time biallelic polymorphism-polymerase chain reaction for chimerism monitoring of hematopoietic stem cell transplantation relapsed patients. Clin. Chim. Acta. 412:625-630, 2011. (SCI; IF = 2.535, Medical Laboratory Technology; Rank 5 of 29)

75.     Liang CJ, Tseng C-P, Yang CM, Ma YH. 20-Hydroxyeicosatetraenoic acid inhibits ATP-induced COX-2 expression via peroxisome proliferator activator receptor-α in vascular smooth muscle cells. Br. J. Pharmacol. 163:815-825, 2011. (SCI; IF = 5.204, Pharmacology and Pharmacy; Rank 19 of 237)

76.     Chang SS, Hsu HL, Cheng JC, Tseng C-P (Corresponding author). An efficient strategy for broad-range detection of low abundance bacteria without DNA decontamination of PCR reagents. Plos One 6: e20303, 2011. (SCI; IF = 4.351, Biology; Rank 10 of 76)

77.     Chen DP, Tseng C-P (Co-first author), Wang WT, Sun CF. Use of Cell Study Models to Confirm the Weak ABO Phenotypes Caused by Point Mutations Among Taiwanese. Ann Clin Lab Sci. Fall;41:346-352, 2011.

78.     Tseng CH, Tseng FH, Chong CK, Tseng C-P, Cheng JC. Angiotensin-converting enzyme genotype and peripheral arterial disease in diabetic patients. Exp Diabetes Res. 2012:698695, 2012.

79.     Yi YH, Chang YS, Lin CH, Lew TS, Tang CY, Tseng WL, Tseng C-P, Lo SJ. Integrin-mediated membrane blebbing is dependent on sodium-proton exchanger 1 and sodium-calcium exchanger 1 activity. J. Biol. Chem. 287:10316-10324, 2012.

80.     Cheng JC, Yeh YJ, Tseng C-P, Hsu SD, Chang YL,  Sakamoto N, Huang HD. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 69:2621-33, 2012.

81.     Liao HR, Chen JJ, Chien YH, Lin SZ, Lin S, Tseng C-P. 5-hydroxy-7-methoxyflavone inhibits N-formyl-l-methionyl-l-leucyl-l-phenylalanine-induced superoxide anion production by specific modulate membrane localization of Tec with a PI3K independent mechanism in human neutrophils. Biochem Pharmacol. 84:182-91. 2012.

82.     Chen DP, Tseng C-P (Co-first author), Wang WT, Sun CF. Genetic and mechanistic evaluation for the mixed-field agglutination in B3 blood type with IVS3+5G>A ABO gene mutation. PLoS One 7:e37272, 2012.

83.     Hung WS, Huang CL, Fan JT, Huang DY, Yeh CF, Cheng JC, Tseng C-P (Corresponding author). The endocytic adaptor protein Disabled-2 is required for cellular uptake of fibrinogen. Biochim Biophys Acta. 2012 Oct;1823(10):1778-88.

84.      Lee TH, Wu TS, Tseng C-P(Co-corresponding author), Qiu JT.High-resolution melting molecular signatures for rapid identification of human papillomavirus genotypes.PLoS One. 2012;7(8):e42051. Epub 2012 Aug 20.

85.     Huang JT, Tseng CP, Liao MH, Lu SC, Yeh WZ, Sakamoto N, Chen CM, Cheng JC.Hepatitis C virus replication is modulated by the interaction of non-structural protein NS5B and fatty acid synthase.J Virol. 2013 Feb 20;87(9):4994-5004.

86.     Lin HC, Hsu HC, Hsieh CH, Wang HM, Huang CY, Wu MH, Tseng CP.A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta. 2013 Feb 13;419C:77-84.

87.     Huang SB, Wu MH, Lin YH, Hsieh CH, Yang CL, Lin HC, Tseng CP, Lee GB.High-purity and label-free isolation of circulating tumor cells (CTCs) in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force. Lab Chip. 2013 Mar 5;13(7):1371-83.

88.     Chang SS, Hsieh WH, Liu TS, Lee SH, Wang CH, Chou HC, Yeo YH, Tseng CP, Lee CC. Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysis. PLoS One. 2013 May 29;8(5):e62323.

89.     Chen DP, Sun CF, Ning HC, Peng CT, Wang WT, Tseng CP. Real-time amplification of glyceraldehyde-3-phosphate dehydrogenase gene for quality control of leukopoor platelets.2013 Jun 19. doi: 10.1111/trf.12294. [Epub ahead of print]